Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
Condition: Diabetes Mellitus, Type 2 Interventions: Drug: Empagliflozin; Drug: Dipeptidyl-peptidase 4 (DPP-4) inhibitors Sponsor: Boehringer Ingelheim Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Jardiance | Middle East Health | Saudi Arabia Health | Study | Urinary Tract Infections